Chronic granulomatous disease explained

Chronic granulomatous disease
Synonyms:	Bridges–Good syndrome, chronic granulomatous disorder, Quie syndrome

Chronic granulomatous disease (CGD), also known as Bridges–Good syndrome, chronic granulomatous disorder, and Quie syndrome,^[1] is a diverse group of hereditary diseases in which certain cells of the immune system have difficulty forming the reactive oxygen compounds (most importantly the superoxide radical due to defective phagocyte NADPH oxidase) used to kill certain ingested pathogens.^[2] This leads to the formation of granulomas in many organs.^[3] CGD affects about 1 in 200,000 people in the United States, with about 20 new cases diagnosed each year.^{[4] [5]}

This condition was first discovered in 1950 in a series of four boys from Minnesota, and in 1957 it was named "a fatal granulomatosus of childhood" in a publication describing their disease.^{[6] [7]} The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease.^[8] Bernard Babior made key contributions in linking the defect of superoxide production of white blood cells, to the cause of the disease. In 1986, the X-linked form of CGD was the first disease for which positional cloning was used to identify the underlying genetic mutation.

Symptoms and signs

Classically, patients with chronic granulomatous disease will have recurrent bouts of infection due to the decreased capacity of their immune system to fight off disease-causing organisms. The recurrent infections they acquire are specific and are, in decreasing order of frequency:

• pneumonia
• abscesses of the skin, tissues, and organs
• septic arthritis
• osteomyelitis
• bacteremia/fungemia
• superficial skin infections such as cellulitis or impetigo

Most people with CGD are diagnosed in childhood, usually, before age 5.^[9] Early diagnosis is important since these people can be placed on antibiotics to ward off infections before they occur. Small groups of CGD patients may also be affected by McLeod syndrome because of the proximity of the two genes on the same X-chromosome.

Atypical infections

People with CGD are sometimes infected with organisms that usually do not cause disease in people with normal immune systems. Among the most common organisms that cause disease in CGD patients are:

• Bacteria (particularly those that are catalase-positive)^[10]
  • Staphylococcus aureus.
  • Serratia marcescens.
  • Listeria species.
  • E. coli.
  • Klebsiella species.
  • Pseudomonas cepacia, a.k.a. Burkholderia cepacia.^[11]
  • Nocardia.^[12]
• Fungi
  • Aspergillus species. Aspergillus has a propensity to cause infection in people with CGD and of the Aspergillus species, Aspergillus fumigatus seems to be most common in CGD.
  • Candida species.

Patients with CGD can usually resist infections of catalase-negative bacteria but are susceptible to catalase-positive bacteria. Catalase is an enzyme that catalyzes the breakdown of hydrogen peroxide in many organisms. In infections caused by organisms that lack catalase (catalase-negative), the host with CGD is successfully able to "borrow" hydrogen peroxide being made by the organism and use it to fight off the infection. In infections by organisms that have catalase (catalase-positive), this "borrowing mechanism" is unsuccessful because the enzyme catalase first breaks down any hydrogen peroxide that would be borrowed from the organism. Therefore in the CGD patient, hydrogen peroxide cannot be used to make oxygen radicals to fight infection, leaving the patient vulnerable to infection by catalase-positive bacteria.

Genetics

Most cases of chronic granulomatous disease are transmitted as a mutation on the X chromosome and are thus called an "X-linked trait".^[9] The affected gene on the X chromosome codes for the gp91 protein p91-PHOX (91 is the weight of the protein in kDa; the gp means glycoprotein). CGD can also be transmitted in an autosomal recessive fashion (via CYBA, NCF1, NCF2 and NCF4) which affect other PHOX proteins. The type of mutation that causes both types of CGD are varied and may be deletions, frame-shift, nonsense, and missense.^{[13] [14]}

A low level of NADPH, the cofactor required for superoxide synthesis, can lead to CGD. This has been reported in women who are homozygous for the genetic defect causing glucose-6-phosphate dehydrogenase deficiency (G6PD), which is characterised by reduced NADPH levels.^[15]

Pathophysiology

Phagocytes (i.e. neutrophils and macrophages) require an enzyme to produce reactive oxygen species to destroy bacteria after they are ingested (phagocytosis), a process known as the respiratory burst. This enzyme is termed "phagocyte NADPH oxidase" (PHOX). This enzyme oxidizes NADPH and reduces molecular oxygen to produce superoxide anions, a reactive oxygen species. Superoxide is then disproportionated into peroxide and molecular oxygen by superoxide dismutase. Finally, peroxide is used by myeloperoxidase to oxidize chloride ions into hypochlorite (the active component of bleach), which is toxic to bacteria. Thus, NADPH oxidase is critical for phagocyte killing of bacteria through reactive oxygen species.

(Two other mechanisms are used by phagocytes to kill bacteria: nitric oxide and proteases, but the loss of ROS-mediated killing alone is sufficient to cause chronic granulomatous disease.)

Defects in one of the four essential subunits of phagocyte NADPH oxidase (PHOX) can all cause CGD of varying severity, dependent on the defect. There are over 410 known possible defects in the PHOX enzyme complex that can lead to chronic granulomatous disease.

Diagnosis

When chronic granulomatous disease (CGD) is suspected, neutrophil-function testing should be carried out, and positive findings should be confirmed by genotyping.^[16] The p47phox mutation is due to a pseudogene conversion, hence it may not be detectable by standard sequencing; in these cases, an immunoblot or gene dose determination may be needed to confirm p47phox deficiency.

Infections caused by the pathogens commonly associated with CGD should prompt functional or genetic screening; neonatal or early postnatal screening of potentially affected children is essential with a family history of CGD.

Neutrophil function tests: These include nitroblue tetrazolium (NBT) reduction test, dihydrorhodamine (DHR) 123 test, direct measurement of superoxide production, cytochrome c reduction assay, and chemiluminescence. DHR test is usually preferred because it is easy to use, objective, and it is able to distinguish between X-linked and autosomal forms of CGD; furthermore, it allows to detect gp91phox carriers.^{[17] [18]}

• The nitroblue-tetrazolium (NBT) test is the original and most widely known test for chronic granulomatous disease.^{[19] [20]} It is negative in CGD, meaning that it does not turn blue. The higher the blue score, the better the cell is at producing reactive oxygen species. This test depends upon the direct reduction of NBT to the insoluble blue compound formazan by superoxide which is produced by normal peripheral blood neutrophils stimulated in vitro; NADPH oxidase catalyzes the aforementioned reaction and NADPH is oxidized in the same reaction. This test is simple to perform and gives rapid results but only tells whether or not there is a problem with the PHOX enzymes, not how much they are affected.
• Dihydrorhodamine (DHR) 123 test: In this test the respiratory burst of the neutrophils is stimulated with phorbol myristate acetate (PMA), resulting in oxidation of dihydrorhodamine 123 (nonfluorescent derivative of rhodamine) to rhodamine 123 (green fluorescent compound), which can be measured by flow cytometry.^[21] This test is abnormal in patients with chronic granulomatous disease (i.e., there is no shift in fluorescence with stimulation). Moreover, its quantitative nature allows to differentiate oxidase-positive from oxidase-negative phagocyte subpopulations in CGD carriers and identify deficiencies in gp91phox and p47phox. Modest residual production of reactive oxygen intermediates (ROI) as assessed by DHR 123 test, is associated with significantly less severe illness and a greater likelihood of long-term survival than patients with little residual ROI production.^[22] On the other hand, in the case of complete myeloperoxidase deficiency, DHR test gives abnormal results (false positive for CGD) because the DHR signal yielded by flow cytometry depends on intact NADPH oxidase activity as well as the presence of a myeloperoxidase (MPO); however, NBT test demonstrates normal production of superoxide.^[23]

Genetic testing

Once CGD has been diagnosed based on abnormal neutrophil function tests, genetic testing should go next. As mentioned above, p47phox defect is usually difficult to identify genetically because it is caused by pseudogene conversion and may be missed in typical sequencing studies; in this case, immunoblotting or flow cytometry can show absence of protein.

Prenatal testing: It is particularly useful when a family member has already been diagnosed with CGD. This test may be performed by analysis of NADPH oxidase activity of neutrophils from fetal blood.^[24] Samples from amniotic fluid or chorionic villi provides an earlier and more reliable diagnosis for families at risk.^[24]

Classification

Chronic granulomatous disease is the name for a genetically heterogeneous group of immunodeficiencies. The core defect is a failure of phagocytic cells to kill organisms that they have engulfed because of defects in a system of enzymes that produce free radicals and other toxic small molecules. There are several types, including:

• X-linked chronic granulomatous disease (CGD)
• autosomal recessive cytochrome b-negative CGD
• autosomal recessive cytochrome b-positive CGD type I
• autosomal recessive cytochrome b-positive CGD type II
• atypical granulomatous disease

Treatment

Management of chronic granulomatous disease revolves around two goals: 1) diagnose the disease early so that antibiotic prophylaxis can be given to keep an infection from occurring, and 2) educate the patient about his or her condition so that prompt treatment can be given if an infection occurs.

Antibiotics

Physicians often prescribe the antibiotic trimethoprim-sulfamethoxazole to prevent bacterial infections.^[25] This drug also has the benefit of sparing the normal bacteria of the digestive tract. Fungal infection is commonly prevented with itraconazole,^[26] although a newer drug of the same type called voriconazole may be more effective.^[27] The use of this drug for this purpose is still under scientific investigation.

Immunomodulation

Interferon, in the form of interferon gamma-1b (Actimmune) is approved by the Food and Drug Administration for the prevention of infection in CGD. It has been shown to reduce infections in CGD patients by 70% and to decrease their severity. Although its exact mechanism is still not entirely understood, it has the ability to give CGD patients more immune function and therefore, greater ability to fight off infections. This therapy has been the standard treatment for CGD for several years.^[28]

Hematopoietic stem cell transplantation (HSCT)

Hematopoietic stem cell transplantation from a matched donor is curative although not without significant risk.^{[29] [30]}

Prognosis

There are currently no studies detailing the long term outcome of chronic granulomatous disease with modern treatment. Without treatment, children often die in the first decade of life. The increased severity of X-linked CGD results in a decreased survival rate of patients, as 20% of X-linked patients die of CGD-related causes by the age of 10, whereas 20% of autosomal recessive patients die by the age of 35.
Recent experience from centers specializing in the care of patients with CGD suggests that the current mortality has fallen to under 3% and 1% respectively.^[31] CGD was initially termed "fatal granulomatous disease of childhood" because patients rarely survived past their first decade in the time before routine use of prophylactic antimicrobial agents. The average patient now survives at least 40 years.^[16]

Epidemiology

CGD affects about 1 in 200,000 people in the United States, with about 20 new cases diagnosed each year.^{[4] [5]}

Chronic granulomatous disease affects all people of all races; however, there is limited information on prevalence outside of the United States. One survey in Sweden reported an incidence of 1 in 220,000 people, while a larger review of studies in Europe suggested a lower rate: 1 in 250,000 people.^[32]

History

This condition was first described in 1954 by Janeway, who reported five cases of the disease in children.^[33] In 1957 it was further characterized as "a fatal granulomatosus of childhood".^{[6] [7]} The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease.^[8] Use of antibiotic prophylaxis, surgical abscess drainage, and vaccination led to the term "fatal" being dropped from the name of the disease as children survived into adulthood.

Research

Gene therapy is currently being studied as a possible treatment for chronic granulomatous disease. CGD is well-suited for gene therapy since it is caused by a mutation in single gene which only affects one body system (the hematopoietic system). Viruses have been used to deliver a normal gp91 gene to rats with a mutation in this gene, and subsequently the phagocytes in these rats were able to produce oxygen radicals.^[34]

In 2006, two human patients with X-linked chronic granulomatous disease underwent gene therapy and blood cell precursor stem cell transplantation to their bone marrow. Both patients recovered from their CGD, clearing pre-existing infections and demonstrating increased oxidase activity in their neutrophils. However, long-term complications and efficacy of this therapy were unknown.^[35]

In 2012, a 16-year-old boy with CGD was treated at the Great Ormond Street Hospital, London with an experimental gene therapy that temporarily reversed the CGD and allowed him to overcome a life-threatening lung disease.^[36]

Notes and References

1. Book: Rapini, Ronald P. . Bolognia, Jean L. . Jorizzo, Joseph L. . Dermatology: 2-Volume Set . Mosby . St. Louis . 2007 . 978-1-4160-2999-1 .
2. Web site: Chronic Granulomatous Disease: Immunodeficiency Disorders: Merck Manual Professional . 2008-03-01 .
3. Heyworth PG, Cross AR, Curnutte JT . Chronic granulomatous disease . Current Opinion in Immunology . 15 . 5 . 578–84 . October 2003 . 14499268 . 10.1016/S0952-7915(03)00109-2 .
4. Pao M, Wiggs EA, Anastacio MM, Hyun J, DeCarlo ES, Miller JT, Anderson VL, Malech HL, Gallin JI, Holland SM . 6 . Cognitive function in patients with chronic granulomatous disease: a preliminary report . Psychosomatics . 45 . 3 . 230–4 . 2004 . 15123849 . 10.1176/appi.psy.45.3.230 .
5. Book: James, William D. . Berger, Timothy G. . Andrews' Diseases of the Skin: clinical Dermatology . Saunders Elsevier . 2006 . 978-0-7216-2921-6 . etal.
6. Berendes H, Bridges RA, Good RA . A fatal granulomatosus of childhood: the clinical study of a new syndrome . Minnesota Medicine . 40 . 5 . 309–12 . May 1957 . 13430573 .
7. Bridges RA, Berendes H, Good RA . A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome . A.M.A. Journal of Diseases of Children . 97 . 4 . 387–408 . April 1959 . 13636694 . 10.1001/archpedi.1959.02070010389004 .
8. Baehner RL, Nathan DG . Leukocyte oxidase: defective activity in chronic granulomatous disease . Science . 155 . 3764 . 835–6 . February 1967 . 6018195 . 10.1126/science.155.3764.835 . 1967Sci...155..835B . 37424151 .
9. Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H . 6 . Chronic granulomatous disease. Report on a national registry of 368 patients . Medicine . 79 . 3 . 155–69 . May 2000 . 10844935 . 10.1097/00005792-200005000-00003 . 39714423 . free .
10. Soler-Palacín P, Margareto C, Llobet P, Asensio O, Hernández M, Caragol I, Español T . Chronic granulomatous disease in pediatric patients: 25 years of experience . Allergologia et Immunopathologia . 35 . 3 . 83–9 . 2007 . 17594870 . 10.1157/13106774 .
11. Lacy DE, Spencer DA, Goldstein A, Weller PH, Darbyshire P . Chronic granulomatous disease presenting in childhood with Pseudomonas cepacia septicaemia . The Journal of Infection . 27 . 3 . 301–4 . November 1993 . 7508484 . 10.1016/0163-4453(93)92271-W .
12. Dorman SE, Guide SV, Conville PS, DeCarlo ES, Malech HL, Gallin JI, Witebsky FG, Holland SM . 6 . Nocardia infection in chronic granulomatous disease . Clinical Infectious Diseases . 35 . 4 . 390–4 . August 2002 . 12145721 . 10.1086/341416 . free .
13. Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, Cross AR . Hematologically important mutations: X-linked chronic granulomatous disease (second update) . Blood Cells, Molecules & Diseases . 27 . 1 . 16–26 . 2001 . 11162142 . 10.1006/bcmd.2000.0347 .
14. Cross AR, Noack D, Rae J, Curnutte JT, Heyworth PG . Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (first update) . Blood Cells, Molecules & Diseases . 26 . 5 . 561–5 . October 2000 . 11112388 . 10.1006/bcmd.2000.0333 .
15. Web site: Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency. The Lecturio Medical Concept Library . 3 September 2020. 23 July 2021.
16. Web site: Zerbe CS, Marciano BE, Holland SM . Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis. . UpToDate . Orange JS, TePas E . Waltham MA . March 17, 2020 .
17. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA . Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes . Journal of Immunological Methods . 178 . 1 . 89–97 . January 1995 . 7829869 . 10.1016/0022-1759(94)00247-t .
18. Vowells SJ, Fleisher TA, Sekhsaria S, Alling DW, Maguire TE, Malech HL . Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease . The Journal of Pediatrics . 128 . 1 . 104–7 . January 1996 . 8551399 . 10.1016/S0022-3476(96)70437-7 .
19. Book: Kasper . Dennis L. . Braunwald . Eugene . Fauci . Anthony S. . Hauser . Stephen L. . Longo . Dan L. . Jameson . J. Larry . Harrison's Principles of Internal Medicine . 2005 . McGraw-Hill Professional . 9780071402354 . 16th. vanc.
20. Baehner RL, Nathan DG . Quantitative nitroblue tetrazolium test in chronic granulomatous disease . The New England Journal of Medicine . 278 . 18 . 971–6 . May 1968 . 4384563 . 10.1056/NEJM196805022781801 .
21. Rothe G, Oser A, Valet G . Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes . Die Naturwissenschaften . 75 . 7 . 354–5 . July 1988 . 3211206 . 10.1007/BF00368326 . 1988NW.....75..354R . 19578466 .
22. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DA, Soule BP, Zarember KA, Malech HL, Holland SM, Gallin JI . 6 . Residual NADPH oxidase and survival in chronic granulomatous disease . The New England Journal of Medicine . 363 . 27 . 2600–10 . December 2010 . 21190454 . 3069846 . 10.1056/NEJMoa1007097 .
23. Mauch L, Lun A, O'Gorman MR, Harris JS, Schulze I, Zychlinsky A, Fuchs T, Oelschlägel U, Brenner S, Kutter D, Rösen-Wolff A, Roesler J . 6 . Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD . Clinical Chemistry . 53 . 5 . 890–6 . May 2007 . 17384005 . 10.1373/clinchem.2006.083444 . free .
24. Roos D, de Boer M . Molecular diagnosis of chronic granulomatous disease . Clinical and Experimental Immunology . 175 . 2 . 139–49 . February 2014 . 24016250 . 3892405 . 10.1111/cei.12202 .
25. Weening RS, Kabel P, Pijman P, Roos D . Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease . The Journal of Pediatrics . 103 . 1 . 127–30 . July 1983 . 6408232 . 10.1016/S0022-3476(83)80798-7 .
26. Cale CM, Jones AM, Goldblatt D . Follow up of patients with chronic granulomatous disease diagnosed since 1990 . Clinical and Experimental Immunology . 120 . 2 . 351–5 . May 2000 . 10792387 . 1905649 . 10.1046/j.1365-2249.2000.01234.x .
27. Sabo JA, Abdel-Rahman SM . Voriconazole: a new triazole antifungal . The Annals of Pharmacotherapy . 34 . 9 . 1032–43 . September 2000 . 10981251 . 10.1345/aph.19237 . 10.1.1.506.9471 . 32446504 .
28. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group . The New England Journal of Medicine . 324 . 8 . 509–16 . February 1991 . 1846940 . 10.1056/NEJM199102213240801 . International Chronic Granulomatous Disease Cooperative Study Group . free .
29. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, Goldblatt D, Parker L, Cant AJ . 6 . Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry . Clinical and Experimental Immunology . 152 . 2 . 211–8 . May 2008 . 18410635 . 2384093 . 10.1111/j.1365-2249.2008.03644.x .
30. Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, Barge D, Spickett GP, Jackson GH, Collin MP, Abinun M, Cant AJ, Gennery AR . 6 . Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth . British Journal of Haematology . 145 . 1 . 73–83 . April 2009 . 19222467 . 10.1111/j.1365-2141.2009.07614.x . free .
31. Modern Management of Chronic Granulomatous Disease by Reinhard Segar, Division of Immunology/Hematology, University Children's Hospital of Zurich, Zurich, Switzerland
32. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, Español T, Fischer A, Kurenko-Deptuch M, Mouy R, Petropoulou T, Roesler J, Seger R, Stasia MJ, Valerius NH, Weening RS, Wolach B, Roos D, Kuijpers TW . 6 . Chronic granulomatous disease: the European experience . PLOS ONE . 4 . 4 . e5234 . 2009 . 19381301 . 2668749 . 10.1371/journal.pone.0005234 . Alspaugh . 2009PLoSO...4.5234V . Andy . free .
33. Assari T . Chronic Granulomatous Disease; fundamental stages in our understanding of CGD . Medical Immunology . 5 . 4 . September 2006 . 16989665 . 1592097 . 10.1186/1476-9433-5-4 . free .
34. Dinauer MC, Gifford MA, Pech N, Li LL, Emshwiller P . Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease . Blood . 97 . 12 . 3738–45 . June 2001 . 11389011 . 10.1182/blood.V97.12.3738 . free .
35. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M . 6 . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 . Nature Medicine . 12 . 4 . 401–9 . April 2006 . 16582916 . 10.1038/nm1393 . 7601162 .
36. News: Sample. Iian. Gene therapy cures life-threatening lung infection in teenage boy. 6 November 2015. The Guardian. 29 February 2012.